Next Article in Journal
Identification of Circular RNA Profiles in the Liver of Diet-Induced Obese Mice and Construction of the ceRNA Network
Next Article in Special Issue
Lack of Association of Polymorphism Located Upstream of ABCA1 (rs2472493), in FNDC3B (rs7636836), and Near ANKRD55MAP3K1 Genes (rs61275591) in Primary Open-Angle Glaucoma Patients of Saudi Origin
Previous Article in Journal
Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL
Previous Article in Special Issue
Missense Variants of von Willebrand Factor in the Background of COVID-19 Associated Coagulopathy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan

1
Department of Pharmacy, University of Peshawar, Peshawar 25000, Pakistan
2
Department of Pharmacy, Qurtaba University of Science and Technology, Peshawar 25000, Pakistan
3
Cardiology Unit Hayatabad Medical Complex, Peshawar 25000, Pakistan
4
Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
5
Department of Environmental Sciences, University of Lakki Marwat KP, Marwat 28420, Pakistan
6
Department of Biotechnology, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
7
Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
*
Author to whom correspondence should be addressed.
Genes 2023, 14(3), 687; https://doi.org/10.3390/genes14030687
Submission received: 29 January 2023 / Revised: 5 March 2023 / Accepted: 6 March 2023 / Published: 10 March 2023

Abstract

:
Coronary Artery Diseases (CAD) remains the top among Non-communicable Diseases (NCDs). Variations in Apolipoprotein E (APOE) and Paroxonase 1 (PON1) have been associated with Myocardial Infarction (MI) in several populations. However, despite the high prevalence of CAD, no such study has been reported in the Pashtun ethnic population of Pakistan. We have conducted a two-stage (i.e., screening and validation) case-control study in which 200 cases and 100 control subjects have been recruited. In the first stage, Whole Exome Sequencing (WES) was used to screen for pathogenic variants of Myocardial Infarction (MI). In the second stage, selected variants of both APOE and PON1 genes (rs7412, rs429358, rs854560, and rs662) were analyzed through MassARRAY genotyping. Risk Allele Frequencies (RAFs) distribution and association of the selected SNPs with MI were determined using the Chi-square test and logistic regression analysis. WES identified a total of 12 sequence variants in APOE and 16 in PON1. Genotyping results revealed that APOE variant rs429358 (ɛ4 allele and ɛ3/ɛ4 genotype) showed significant association in MI patients (OR = 2.11, p value = 0.03; 95% CI = 1.25–2.43); whereas no significant difference (p˃ 0.05) was observed for rs7412. Similarly, the R allele of PON1 Q192R (rs662) was significantly associated with cases (OR = 1.353, p value = 0.048; 95% CI = 0.959–1.91), with particular mention of RR genotype (OR = 1.523, p value = 0.006; 95% CI = 1.087–2.132). Multiple logistic regression analysis showed that rs429358 (C allele) and rs662 (R allele) have a significantly higher risk of MI after adjustment for the conventional risk factors. Our study findings suggested that the rs429358 variant of APOE and PON1 Q192R are associated with MI susceptibility in the Pashtun ethnic population of Pakistan.

1. Introduction

Non-communicable diseases (NCDs) are becoming the leading cause of mortality, disability, decreased quality of life, and growing healthcare expenses throughout the world [1]. The global mortality rate from these causes is double that of infectious illnesses, and nutritional deficiencies combined [2]. The most frequent among them include cardiovascular diseases (CVDs) are diabetes, malignancies, and chronic respiratory disorders [3]. They are the major cause of mortality in industrialized countries and the second largest cause in developing and underdeveloped nations, accounting for about 74.4% of all fatalities in 2019, which increased by 20.5% from 2009 to 2019 [4].
Coronary Artery Disease (CAD) is a class of CVD which include Myocardial Infarction (MI), hypertension (HTN), and congenital heart disease. Pathology defines MI as myocardial cell loss caused by persistent ischemia [5]. MI is well-known throughout the world for its high mortality and disability rates and is one of the top 10 causes of death in Pakistan [2,6]. There were 4 million MI-related fatalities between 1999 and 2019 [7].
Lifestyle, environmental, and genetic factors have a key role in the development of CVD [8]. Among the former, some major factors to mention are physical activity, diet, smoking habits, obesity, etc. About the latter, information from different studies has recommended a 40–80% genetic link [9,10]. A person with parental history of premature atherosclerosis has a 1.5- to 2-fold risk of developing the same [11]. Risk can easily be predicted through a better understanding of the genetic components [12,13]. In the last decades, human genetics approaches have recognized genes that have possible contributions towards developing MI [14]. Some of these include variants of different genes such as Apolipoprotein (APOE), Paroxonase 1 (PON1), Cytochrome P4501A1 (CYP1A1), interleukin-6, Cholesteryl Ester Transfer Protein (CETP) and many others [15,16,17,18,19].
One of the major cause of the development of CAD is Atherosclerosis which is a pathological procedure in which lipid is accumulated in the intima and media of the blood vessel and thus leads to the formation of plaques [20]. Both youth and adolescents may develop coronary atherosclerosis [21]. Abnormalities in two proteins, namely APOE and human PON1, play an important role in its development [22,23]. APOE is a serum glycoprotein that plays an important role in the transport and metabolism of lipids and is encoded by the APOE gene, which is located on chromosome 19. Exon 4 of the gene has two common SNPs: rs429358 (388 T > C) and rs7412 (526 C > T). Moreover, three alleles (ɛ2(388 T–526 T), ɛ3(388 T-526C), ɛ4(388C-526C)) and six genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ɛ3, ɛ3/ɛ4 and ɛ4/ɛ4) can be formed by the two SNPs [24,25]. Since allele 3 is the most prevalent in populations, it is referred to as “wild-type.”The alleles 2 and 4 are considered variants [26]. Various studies have reported their association with MI in different ethnicities such as Chinese and Russian etc. [27,28]. Similarly, PON1 is a membrane-bound glycoprotein encoded by the PON1 gene that is located on chromosome 7q21.3-q22.1 [29,30]. It is associated with highly-density lipoprotein (HDL) and is found in a variety of tissues but is predominantly synthesized in the liver [31]. It inhibits the concentration of low-density lipoprotein cholesterol (LDL-C) by hydrolysis of lipid peroxides [31]. PON1 has considerable anti-inflammatory and anti-oxidative actions through its enzymatic Paroxonase, lactonase, and esterase activities [29]. There is some evidence of low serum PON1 activity in patients with lipid disorders such as diabetes mellitus (DM), MI, atherosclerosis, and familial hypercholesterolemia [30]. PON1 gene has two common polymorphisms, namely L55M and Q192R, of which L55L and Q192Q are regarded as wild type, and Q192R, R192R, L55M, and M55M are considered variant genotypes [8,32,33].
To the best of our knowledge, no such study hasreported the association of these variants in the Pashtun population of Khyber Pakhtunkhwa (KP), Pakistan, despite the reports of increasing incidence of CAD in recent years [34,35]. Owing to their unique cultural practices, social values, lifestyle, and behaviors make them suitable for such studies [34,36]. Considering the importance of the above-mentioned gene variants, it seems suitable to know their association with MI in the said population.
Therefore, this case-control study has been designed to investigate the possible association of APOE and PON1 variants with the risk of MI in the Pashtun ethnic population of KP, Pakistan.

2. Materials and Methods

2.1. Ethics Statement

Ethical approval was obtained from the Ethical Committee of the Department of Pharmacy, University of Peshawar (No: 906/Pham). Written informed consent was obtained from all the study subjects. The study was conducted in compliance with the ethical guidelines of the 1975 Declaration of Helsinki.

2.2. Study Population

A total of 300 age and gender-matched individuals (n = 200 MI cases and n = 100 healthy controls) of Pashtun ethnicity belonging from different districts such as Peshawar, Mardan, Swabi, Charsadda, Nowshehra, Swat, and others of Khyber Pakhtunkhwa were included in the study. The study period was from July 2018 to July 2019. The mean age of the control subjects was 58.43 ± 12.65 (140 males and 60 females), and the control was 56.63 ± 11.87(63 males and 37 females). The diagnosis of MI was based on the American College of Cardiology/American Heart Association (ACC/AHA) classification. A senior cardiologist diagnosed MI based on medical records that revealed medical indications, abnormal cardiac enzymes, ECG (Electrocardiogram) abnormalities, and angiography/echocardiography results. CAD was defined as stenosis ˃50% in at least one of the significant segments of the coronary artery. The control subjects had no lumen stenosis (˂50%) on coronary angiography or physical indications of cardiovascular disease. HTN was defined as having a mean blood pressure of ≥140/90 mmHg or being currently treated for it. DM was classified as having fasting glucose levels of ≥126 mg/dL or non-fasting glucose levels of ≥200 mg/dL, as well as being on oral hypoglycemic medicines or insulin. Patients were admitted tothe three tertiary care (teaching) hospitals of Khyber Pakhtunkhwa, Lady Reading Hospital (LRH) Peshawar, Hayatabad Medical Complex (HMC) Peshawar, and Khyber Teaching Hospital (KTH) Peshawar, while control samples were collected from different districts. Healthy volunteers had no history of cardiovascular disease, especially MI. Inclusion criteria for cases were (i) confirmed MI patients, (ii) Patients belonging to Pakistani Pashtun origin (iii) age ≥30 years. Exclusion criteria were (i) Age ˃80 and ˂30, (ii) mentally ill patients, (iii) severe liver diseases, (iv) malignant tumor, and (v) renal dysfunction. The consent form and thorough demographic, family, and clinical history of all the participants was taken on a carefully designed Proforma. Demographic information includes age, weight, height, and residence. A family history questionnaire includes information on any CVD, MI, or other cardiac issues in the family. The clinical history section of the Proforma includes details about the current disease, co-morbid disorders, and vital signs. For illiterate participants, who have difficulty understanding English, the consent form for their understanding was read and explained in the local Pashtu language and then signed on his/her behalf by any of his/her relatives/attendants.

2.3. Blood Sampling

Following an overnight fast, blood samples were collected from each research participant through venipuncture, with 2.5 mL collected in each EDTA (Ethylene diamine tetra acetic acid) tube and plain tube (without anticoagulant). After allowing the blood in the plain tube to clot, it was centrifuged to obtain serum for biochemical examination. Following aseptic procedures, blood samples (properly labeled) were stored at −10 °C.

2.4. DNA Extraction and Biochemical Measurements

Genomic DNA (Deoxyribonucleic acid) was extracted from peripheral blood leukocytes using the WizPrep DNA extraction kit (WizPrep no. W54100). DNA measurements were carried out with the Qubit ™ dsDNA HS Assay kit (Catalog No. Q32851), and the concentration was adjusted to 10 ng/μL.The serum concentration of Total Cholesterol (TC), Triglycerides (TG), LDL-C, and high-density lipoprotein cholesterol (HDL-C) were measured by standard enzymatic methods using standard reagents on Architect Plus (Ci-4100, Germany) biochemical instrument following strictly manufacturer’s instructions in Hospital clinical laboratory.

2.5. DNA Samples Pooling

According to the DNA-pooling techniques previously described [37], DNA pools were created from 200 MI patients and 100 control participants in order to cut costs and streamline the sequencing procedure. Each pool contains an equal quantity of genomic DNA (10 ng) from each subject.

2.6. Variant Prioritization

The annotated data in the Excel file were first manually curated to screen exonic, and missense variants and synonymous variants were eliminated as shown in Figure 1. The functional influence, biological action, and pathogenicity of the selected variants (SNPs) were checked by using prediction algorithms (PolyPhen and SIFT prediction) built within ANNOVAR.

2.7. Validation Trial and Genotyping of APOE and PON1

In the research population, Whole Exome Sequencing (WES) discovered a total of 12 variations in the APOE and 16 in the PON1 gene, respectively. The selected SNPs were genotyped to validate WES results and confirm the association with MI. Sequenom MassARRAY (Sequenom Inch., San Diego, CA, USA) platform was employed following the manufacturer’s instructions.

2.8. Statistical Analysis

The SPSS (Statistical Package for the Social Sciences) software was used to analyze statistical data. Age, gender, weight, smoking, lifestyle, exercise, PON1, and APOE gene variations were the main factors chosen for the study. W Shapiro-Wilk’s test was used to determine the normality of distribution for quantitative data. Categorical data of the cases and control individuals were reported as percentages and frequencies and analyzed with a Chi-square test., whereas continuous variables were displayed as mean standard ± deviation. Odds ratios (OR) of MI cases for each variant using a binary logistic regression model were estimated with a 95% confidence interval (CI). The difference in genotype and allelic prevalence and correlation between cases and control were assessed independently as well as adjusted for conventional risk factors. Age, gender, smoking, and family history of MI, TC, and LDL-C were included as covariates, as well as all the possible genotypes studied. Binary logistic regression was used to determine if the chosen SNP was associated with MI. A p ≤ 0.05 was statistically considered significant.

3. Results

3.1. Population Characteristics

Co-morbidities and Sociodemographic characteristics of study subjects are described briefly in Table 1 and Table 2. The prevalence of co-morbidities such as HTN (55% vs. 36%) and DM (47.5% vs. 32%) were higher in cases as compared to the control subjects. The majority of the subject cases hada family history of MI (55.5%). Moreover, 80% of CAD cases were taking anti-hyperlipidemic medicines (statins) to maintain their poor lipid profile, due to which CAD patients might show normal values of lipid parameters. Moreover, the majority (70%) had a sedentary lifestyle. Furthermore, most of the male patients (58.5%) were smokers. Almost half of the patients were totally non-compliant withdiet and medicines.

3.2. WES Results

WES identified a total of 33,329 exonic SNPs, including 3600 homozygous, 29,729 heterozygous, 31,488 synonymous, 1086 deletion, 68 pathogenic, 3456 missenses, and 460 probably damaging variants. A total of 12 variants were identified in APOE and 16 in PON1, as shown in Table 3 and Table 4. Detailed WES results are shown in Figure 2.

3.3. Genotype and Allele Frequencies of APOE (rs429358 and rs7412) and Their Association with MI

Both the APOE gene variants (rs429358 and rs7412) were checked for their association with MI by using logistic regression analysis. The genotypic and allelic distributions of both variants are displayed in Table 5. In our study population, the ɛ3 allele is the most common. The results are in broad agreement with data on the frequency ɛ3 allele globally [38]. A significant difference was observed for the variant genotype ɛ3/ɛ4 [OR (95% CI) = 2.13 (1.32–2.65): p = 0.031)] and ɛ4 allele [OR (95% CI) = 2.11 (1.25–2.43): p = 0.03)] of APOE in MI patients compared to control; Whereas other genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ2/ɛ2, and ɛ3/ɛ3) and allele (ɛ2) showed no statistically significant difference (all p > 0.05).

3.4. Association of L55M and Q192R Variants of PON1 with MI (SNP×MI)

Both the PON1 gene variants (L55M and Q192R) were checked for their association with MI by using logistic regression analysis. The genotypic and allelic distributions of both variants are displayed in Table 6. The allele and genotype distribution of PON1 Q192R was found to be significantly different between the MI cases and control subjects. The frequency of the R allele was found to be significantly higher in the study subjects than in the controls. Moreover, the RR genotype was found more frequently in the MI cases than in the controls (16% vs. 9%). By binary logistic regression analysis, the Q192R genotype of the PON1 gene was found to be significantly associated with MI cases [OR (95% CI), 1.353 (0.959–1.910): p = 0.048]. There was no significant difference between the MI cases and controls for the L allele and M allele. The results showed no significant association of the PON1 L55M genotypes with MI (p ˃ 0.05).

3.5. Logistic Regression Analysis for MI in Pashtun Population

Logistic regression analysis was performed to determine independent predictors for MI in the study population. On univariate regression analysis, there was a significantly higher risk of MI in the presence of age, gender, smoking, family history of MI, HTN, DM, rs429358 (e4 allele), and rs662 (R allele). Further multivariable analysis showed that participants with ɛ4 and R alleles of rs429358 and rs662 had a significantly higher risk of MI after adjustment for the established conventional risk factors, as shown in Table 7.

4. Discussion

The current study investigated the relationship between APOE and PON1 polymorphism and the risk of MI in Pakistan’s Pashtun ethnic population. The genes were selected for genotype validation due to their prominent association with other ethnicities along with data absence in the study population. The selected variants of APOE (rs7412 and rs429358) were genotyped and validated by MassARRAY to confirm the association with MI. The notable variant among the 12 identified variants of APOE was rs429358 (p.Cys130Arg), located on the 4th exon of chromosome 19. SIFT and PolyPhen predicted the variant rs429358 as deleterious and probably damaging, respectively. Likewise, another exonic missense SNP reported was rs7412 (p.Arg176Cys). SIFT and PolyPhen labeled them deleterious and benign, respectively. Furthermore, a significant association between the ɛ4 allele (rs429358) and the risk of MI has been found in the study population, which is in broad agreement with other ethnic populations [27,39,40]. This association remained significant when adjusted for several MI confounding factors.
The APOE gene polymorphisms are associated with many diseases such as dementia, Parkinson’s disease, epilepsy, and CAD [41]. Its association with MI or CAD has been extensively studied in the last two decades, and the ϵ4 allele has been found to have a link with it in many studies [42]. Moreover, the same allele was associated with an increased risk of developing HTN [43]. A large-scale genomic study comprising 32,965 controls and 15,492 cases showed that individuals with the ϵ4 allele had a higher risk for coronary heart disease (CHD) compared to individuals with the ϵ3/ϵ3 genotype [44]. However, another study has shown no association of APOE gene polymorphism with the development of CAD in the study on the relationship between APOE gene polymorphism and blood lipid and CAD in African Caribbean people [45]. These inconsistencies may be because of regional and ethnic variability. This study found the ɛ3 allele to be the most common isoform of the APOE gene accounting for 73% of cases and 81% in controls, respectively, which was consistent with most of the previous studies [40,46]. The findings of our study regarding the frequencies of APOE allele are consistent with that of other ethnicities [47,48].
Similarly, this study has also assessed the association of Q192R and L55M variants. Findings suggested the missense SNPQ192R (rs662), located on the short arm of chromosome 7 as significant. The frequency of the RR genotype of Q192R was found to be higher in the MI cases compared to the control. The Q192R (rs662) polymorphism cases with MI revealed a higher frequency of the R allele compared to the control. Both the SIFT and PolyPhen scores predicted it as pathogenic and damaging, respectively. The second missense, exonic SNP, was L55M (rs854560). It was shown tolerable and benign by SIFT and PolyPhen score, respectively, and was found not associated with MI (p ˃ 0.05). This finding is supported by other studies [23]. Studies conducted in different ethnic populations have shown interesting results of the association of Q192R polymorphism of PON1 with MI [49]. Many studies have revealed the RR genotype and R allele of PON Q192R with susceptibility to MI [23]. A study conducted on the Colombian ethnic population proposed Q192R polymorphism of PON1 as a useful biomarker of CAD [50]. Another study also showed an association of the PON Q192R variant with CAD [51]. In line with these findings, a significant association was observed for Q192R with CAD by Liu and colleagues [52]. Similar findings were also found in a Chinese ethnic population, south Indian Tamil, and Asian Indians. [53,54,55] Conversely, many other studies have demonstrated conflicting findings and found no association of PON1 Q192R polymorphism with CAD [23]. In particular, a genetic study conducted on 120 CAD and 102 healthy volunteers revealed that PON1 192R allele frequency was the same among the cases and control [56]. Furthermore, no link was found between the Q192R polymorphism and CAD in a Turkish population [57]. Similarly no association was observed in Taiwan ethnic population [58].
Furthermore, Sociodemographic analysis of cases and controls revealed a higher incidence of DM and HTN in cases compared to the control. Moreover, the results showed an increased prevalence of MI in males compared to females (70% vs. 30%). Most of the MI patients were smokers compared to controls (58.5% vs. 26%). Furthermore, a family history of MI and other heart diseases was more prevalent in some cases. Physically activity (exercise) was found to be very poor in cases compared to controls (30% vs. 70%).

5. Conclusions

The present study has suggested that APOE variant rs429358 and PON1 variant Q192R are associated with MIrisk in the Pashtun population of KP and may be further studied to determine their potential as susceptibility biomarkers for the same.

Limitations

The small sample size is a limitation of our study; similarly, we did not measure the corresponding protein level to know about the expression of the proteins. Moreover, the study was conducted only on patients of Pashtun ethnicity, so it cannot be generalized to the whole of Pakistan or other ethnic populations.

Author Contributions

Conceptualization, N.R. and A.J.; methodology, A.J.; software, Z.; validation, N.R., Z. and A.J.; formal analysis, R.A. and J.I.; investigation, M.A.K.; resources, M.S.; data curation, F.K., S.A. and Z.P.; writing—original draft preparation, N.R. and A.J. writing—review and editing, W.A.S. and J.I.; visualization, Z.P. and S.A.; supervision, Z. and A.J.; project administration, M.S.; funding acquisition, A.J. All authors have read and agreed to the published version of the manuscript.

Funding

The study was approved and financially supported by Higher Education Commission of Pakistan (Project≠20-6691/R&D/NRPU/HEC/2017).

Institutional Review Board Statement

Ethical approval was obtained from Ethical Committee, Department of Pharmacy (Approval No. 906/Pharm).

Informed Consent Statement

Informed consent was obtained.

Data Availability Statement

All data is available with manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Boon, M.R.; Bakker, L.E.; van der Linden, R.A.; van Ouwerkerk, A.F.; de Goeje, P.L.; Counotte, J.; Jazet, I.M.; Rensen, P.C. High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue? Crit. Rev. Clin. Lab. Sci. 2015, 52, 150–157. [Google Scholar] [CrossRef] [PubMed]
  2. Mokdad, A.H. Global non-communicable disease prevention: Building on success by addressing an emerging health need in developing countries. J. Health Speéc. 2016, 4, 92. [Google Scholar] [CrossRef]
  3. Wagner, K.-H.; Brath, H. A global view on the development of non communicable diseases. Prev. Med. 2012, 54, S38–S41. [Google Scholar] [CrossRef] [PubMed]
  4. Qiao, J.; Lin, X.; Wu, Y.; Huang, X.; Pan, X.; Xu, J.; Wu, J.; Ren, Y.; Shan, P.F. Global burden of non-communicable diseases attributable to dietary risks in 1990–2019. J. Hum. Nutr. Diet. 2022, 35, 202–213. [Google Scholar] [CrossRef] [PubMed]
  5. Tehrani, D.M.; Seto, A.H. Third universal definition of myocardial infarction: Update, caveats, differential diagnoses. Clevel. Clin. J. Med. 2013, 80, 777–786. [Google Scholar] [CrossRef]
  6. Jafary, M.H.; Samad, A.; Ishaq, M.; Jawaid, S.A.; Ahmad, M.; Vohra, E.A. Profile of acute myocardial infarction (AMI) in Pakistan. Pak. J. Med. Sci. 2007, 23, 485. [Google Scholar]
  7. Dani, S.S.; Lone, A.N.; Javed, Z.; Khan, M.S.; Zia Khan, M.; Kaluski, E.; Virani, S.S.; Shapiro, M.D.; Cainzos-Achirica, M.; Nasir, K. Trends in Premature Mortality From Acute Myocardial Infarction in the United States, 1999 to 2019. J. Am. Heart Assoc. 2022, 11, e021682. [Google Scholar] [CrossRef]
  8. Wang, Q. Molecular genetics of coronary artery disease. J.Curr. Opin. Cardiol. 2005, 20, 182–188. [Google Scholar] [CrossRef] [Green Version]
  9. Anderson, R.N.; Smith, B.L. Deaths: Leading Causes for 2001; DHHS Publication: Hyattsville, MA, USA, 2003. [Google Scholar]
  10. Roberts, R.; Fair, J. Genetics, its role in preventing the pandemic of coronary artery disease. Clin. Cardiol. 2021, 44, 771–779. [Google Scholar] [CrossRef]
  11. Khera, A.; Ajufo, E. Family History of Premature Atherosclerotic Cardiovascular Disease. In Cardiovascular Risk Assessment in Primary Prevention; Springer: Berlin/Heidelberg, Germany, 2022; pp. 149–175. [Google Scholar] [CrossRef]
  12. Frostegård, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013, 11, 117. [Google Scholar] [CrossRef] [Green Version]
  13. Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006, 47, C7–C12. [Google Scholar] [CrossRef] [Green Version]
  14. Topol, E.J.; Smith, J.; Plow, E.F.; Wang, Q.K. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum. Mol. Genet. 2006, 15, R117–R123. [Google Scholar] [CrossRef]
  15. Kolovou, G.; Yiannakouris, N.; Hatzivassiliou, M.; Malakos, J.; Daskalova, D.; Hatzigeorgiou, G.; Cariolou, M.A.; Cokkinos, D.V. Association of Apolipoprotein E Polymorphism with Myocardial Infarction in Greek Patients with Coronary Artery Disease. Curr. Med. Res. Opin. 2002, 18, 118–124. [Google Scholar] [CrossRef]
  16. Su, J.; Li, J.; Yu, Q.; Xu, X.; Wang, J.; Yang, J.; Li, X.; Chen, X. Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. J. Clin. Lab. Anal. 2019, 33, e22867. [Google Scholar] [CrossRef] [Green Version]
  17. Eskandari, M.; Mellati, A.A.; Mahmoodi, K.; Kamali, K.; Soltanpour, M.S. Association of the CYP1A1 rs4646903 polymorphism with susceptibility and severity of coronary artery disease. Mol. Biol. Res. Commun. 2021, 10, 55–61. [Google Scholar] [CrossRef]
  18. Ridker, P.M.; Rane, M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ. Res. 2021, 128, 1728–1746. [Google Scholar] [CrossRef]
  19. Cupido, A.J.; Reeskamp, L.F.; Hingorani, A.D.; Finan, C.; Asselbergs, F.W.; Hovingh, G.K.; Schmidt, A.F. Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: A factorial Mendelian randomization study. JAMA Cardiol. 2022, 7, 955–964. [Google Scholar] [CrossRef]
  20. Garcia, J.; Khang-Loon, H. Carotid atherosclerosis. Definition, pathogenesis, and clinical significance. Neuroimaging Clin. North Am. 1996, 6, 801–810. [Google Scholar]
  21. Thomas, J.B.; Antiga, L.; Che, S.L.; Milner, J.S.; Hangan Steinman, D.A.; Spence, J.D.; Rutt, B.K.; Steinman, D.A. Variation in the carotid bifurcation geometry of young versus older adults: Implications for geometric risk of atherosclerosis. Stroke 2005, 36, 2450–2456. [Google Scholar] [CrossRef] [Green Version]
  22. Tsai, C.-Y.; Huang, D.-Y.; Ho, J.-A.A.; Wu, L.-C. Evaluation of the apolipoprotein E (apoE)-HDL-associated risk factors for coronary heart disease using duo-functional electrochemical aptasensor. J. Anal. Bioanal. Chem. 2022, 414, 5595–5607. [Google Scholar] [CrossRef]
  23. Godbole, C.; Thaker, S.; Kerkar, P.; Nadkar, M.; Gogtay, N.; Thatte, U. Association of PON1 gene polymorphisms and enzymatic activity with risk of coronary artery disease. Future Cardiol. 2020, 17, 119–126. [Google Scholar] [CrossRef] [PubMed]
  24. Seripa, D.; D’Onofrio, G.; Panza, F.; Cascavilla, L.; Masullo, C.; Pilotto, A. The Genetics of the Human APOE Polymorphism. Rejuvenation Res. 2011, 14, 491–500. [Google Scholar] [CrossRef] [PubMed]
  25. Liu, Q.; Wu, H.; Yu, Z.; Huang, Q.; Zhong, Z. APOE gene ɛ4 allele (388C-526C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population. J. Clin. Lab. Anal. 2021, 35, e23925. [Google Scholar] [CrossRef] [PubMed]
  26. Shao, A.; Shi, J.; Liang, Z.; Pan, L.; Zhu, W.; Liu, S.; Xu, J.; Guo, Y.; Cheng, Y.; Qiao, Y. Meta-analysis of the association between Apolipoprotein E polymorphism and risks of myocardial infarction. BMC Cardiovasc. Disord. 2022, 22, 126. [Google Scholar] [CrossRef]
  27. Yin, Y.-W.; Sun, Q.-Q.; Zhang, B.-B.; Hu, A.-M.; Liu, H.-L.; Wang, Q.; Hou, Z.-Z. Association between Apolipoprotein E Gene Polymorphism and the Risk of Coronary Artery Disease in Chinese Population: Evidence from a Meta-Analysis of 40 Studies. PLoS ONE 2013, 8, e66924. [Google Scholar] [CrossRef] [Green Version]
  28. Stepanov, V.; Puzyrev, V.; Karpov, R.S.; Kutmin, A.I. Genetic markers in coronary artery disease in a Russian population. Hum. Biol. 1998, 70, 47–57. [Google Scholar]
  29. Ściskalska, M.; Milnerowicz, H. Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein AI (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis. Genes 2022, 13, 1968. [Google Scholar] [CrossRef]
  30. Wysocka, A.; Cybulski, M.; Wysokiński, A.P.; Berbeć, H.; Stążka, J.; Zapolski, T. Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery. J. Clin. Med. 2019, 8, 441. [Google Scholar] [CrossRef] [Green Version]
  31. Otocka-Kmiecik, A. Effect of Carotenoids on Paraoxonase-1 Activity and Gene Expression. Nutrients 2022, 14, 2842. [Google Scholar] [CrossRef]
  32. Arca, M.; Ombres, D.; Montali, A.; Campagna, F.; Mangieri, E.; Tanzilli, G.; Campa, P.P.; Ricci, G.; Verna, R.; Pannitteri, G. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur. J. Clin. Investig. 2002, 32, 9–15. [Google Scholar] [CrossRef]
  33. Wang, Q.; Chen, Q. Cardiovascular disease and congenital defects. Nat. Encycl. Life Sci. 2000, 3, 646–657. [Google Scholar]
  34. Khan, S.B.; Habib, S.A.; Jibran, M.S.; Ali, I. Trends of Coronary Artery Disease in Khyber Pakhtunkhwa, Pakistan: A Retrospective Study. Khyber Med. Univ. J. 2019, 11, 214–217. [Google Scholar]
  35. Ullah, S.A.; Shah, S.T.; Khan, S.; Khalil, A.A. Frequency and Pattern of Coronary Artery Disease and Its Associated Risk Factors in Stable Ischemic Heart Disease Patients Undergoing Coronary Angiography: A Cross Sectional Study. J. Khyber Coll. Dent. 2020, 10, 1–6. [Google Scholar]
  36. Jan, A.; Zakiullah; Ali, S.; Muhammad, B.; Arshad, A.; Shah, Y.; Bahadur, H.; Khan, H.; Khuda, F.; Akbar, R.; et al. Decoding type 2 diabetes mellitus genetic risk variants in Pakistani Pashtun ethnic population using the nascent whole exome sequencing and MassARRAY genotyping: A case-control association study. PLoS ONE 2023, 18, e0281070. [Google Scholar] [CrossRef]
  37. Jan, A.; Saeed, M.; Afridi, M.H.; Khuda, F.; Shabbir, M.; Khan, H.; Ali, S.; Hassan, M.; Samiullah, U.; Akbar, R.; et al. Association of HLA-B Gene Polymorphisms with Type 2 Diabetes in Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan. J. Diabetes Res. 2021, 2021, 6669731. [Google Scholar] [CrossRef]
  38. Karjalainen, J.-P.; Mononen, N.; Hutri-Kähönen, N.; Lehtimäki, M.; Juonala, M.; Ala-Korpela, M.; Kähönen, M.; Raitakari, O.; Lehtimäki, T. The effect of apolipoprotein E polymorphism on serum metabolome–a population-based 10-year follow-up study. Sci. Rep. 2019, 9, 458. [Google Scholar] [CrossRef] [Green Version]
  39. Hou, J.; Deng, Q.; Guo, X.; Deng, X.; Zhong, W.; Zhong, Z. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Hakka postmenopausal women in southern China. Lipids Health Dis. 2020, 19, 139. [Google Scholar] [CrossRef]
  40. Marais, A.D. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. J.Pathology 2019, 51, 165–176. [Google Scholar] [CrossRef]
  41. Tang, Y.; Li, Y.-M.; Zhang, M.; Chen, Y.-Q.; Sun, Q. ε3/4 genotype of the apolipoprotein E is associated with higher risk of Alzheimer’s disease in patients with type 2 diabetes mellitus. Gene 2019, 703, 65–70. [Google Scholar] [CrossRef]
  42. Lahoz, C.; Schaefer, E.J.; Cupples, L.; Wilson, P.W.; Levy, D.; Osgood, D.; Parpos, S.; Pedro-Botet, J.; Daly, J.A.; Ordovas, J.M. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154, 529–537. [Google Scholar] [CrossRef]
  43. Raz, N.; Rodrigue, K.M.; Kennedy, K.M.; Land, S. Genetic and vascular modifiers of age-sensitive cognitive skills: Effects of COMT, BDNF, ApoE, and hypertension. Neuropsychology 2009, 23, 105–116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Song, Y.; Stampfer, M.J.; Liu, S. Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease. Ann. Intern. Med. 2004, 141, 137–147. [Google Scholar] [CrossRef] [PubMed]
  45. Larifla, L.; Armand, C.; Bangou, J.; Blanchet-Deverly, A.; Numeric, P.; Fonteau, C.; Michel, C.-T.; Ferdinand, S.; Bourrhis, V.; Vélayoudom-Céphise, F.-L. Association of APOE gene polymorphism with lipid profile and coronary artery disease in Afro-Caribbeans. PLoS ONE 2017, 12, e0181620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Griffin, B.A.; Walker, C.G.; Jebb, S.A.; Moore, C.; Frost, G.S.; Goff, L.; Sanders, T.A.; Lewis, F.; Griffin, M.; Gitau, R. APOE4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein B than wild type (E3/E3), after replacement of dietary saturated fats with low glycaemic index carbohydrates. Nutrients 2018, 10, 1524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Zhou, J.; Xue, Y.-L.; Guan, Y.-X.; Yang, Y.-D.; Fu, S.-B.; Zhang, J.-C. Association study of apolipoprotein e gene polymorphism and cerebral infarction in type 2 diabetic patients. Yi Chuan = Hereditas 2005, 27, 35–38. [Google Scholar]
  48. Wu, H.; Huang, Q.; Yu, Z.; Wu, H.; Zhong, Z. The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population. J. Lipids Health Dis. 2020, 19, 20. [Google Scholar] [CrossRef]
  49. Muheeb, G.; Gupta, M.D.; Kunal, S.; Basia, D.; Mp, G.; Bansal, A.; Yusuf, J.; Mukhopadhyay, S.; Tyagi, S.; Singh, R. Novel lipid biomarkers and associated gene polymorphism in young ST-segment elevation myocardial infarction. Indian Heart J. 2022, 75, 68–72. [Google Scholar] [CrossRef]
  50. Corredor-Orlandelli, D.; Sambracos-Parrado, S.; Mantilla-García, S.; Tovar-Tirado, J.; Vega-Ramírez, V.; Mendoza-Ayús, S.D.; Peña, L.C.; Leal, M.F.; Rodríguez-Carrillo, J.; León-Torres, J.; et al. Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population. Vasc. Health Risk Manag. 2021, 17, 689–699. [Google Scholar] [CrossRef]
  51. Mackness, B.; Davies, G.K.; Turkie, W.; Lee, E.; Roberts, D.H.; Hill, E.; Roberts, C.; Durrington, P.N.; Mackness, M.I. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1451–1457. [Google Scholar] [CrossRef] [Green Version]
  52. Liu, T.; Zhang, X.; Zhang, J.; Liang, Z.; Cai, W.; Huang, M.; Yan, C.; Zhu, Z.; Han, Y. Association between PON1 rs662 polymorphism and coronary artery disease. Eur. J. Clin. Nutr. 2014, 68, 1029–1035. [Google Scholar] [CrossRef]
  53. Pan, Y.; He, B.; Sun, H.; Xu, T.; Pan, B.; Wang, S.; Mei, Y. Susceptibility of PON1/PON2 genetic variations to ischemic stroke risk in a Chinese Han population. Pharm. Pers. Med. 2020, 13, 563–570. [Google Scholar]
  54. Sharma, A.R.; Vohra, M.; Shukla, V.; Guddattu, V.; Uk, A.R.; Shetty, R.; Umakanth, S.; Satyamoorthy, K.; Rai, P.S. Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. J.Life Sci. 2020, 245, 117364. [Google Scholar] [CrossRef]
  55. Raza, S.T.; Abbas, S.; Wani, I.A.; Eba, A.; Mahdi, F. Clinical implications of PON1 (rs662) and TNF-α (rs1799964) genes polymorphism in patients with coronary artery disease. Egypt. J. Med. Hum. Genet. 2022, 23, 107. [Google Scholar] [CrossRef]
  56. Taşkiran, P.; Cam, S.F.; Sekuri, C.; Tüzün, N.; Alioğlu, E.; Altintaş, N.; Berdeli, A. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol. Dern. Ars.-Arch. Turk. Soc. Cardiol. 2009, 37, 473–478. [Google Scholar]
  57. Van Himbergen, T.M.; Roest, M.; de Graaf, J.; Jansen, E.H.J.M.; Hattori, H.; Kastelein, J.J.P.; Voorbij, H.A.M.; Stalenhoef, A.F.H.; van Tits, L.J.H. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 2005, 46, 445–451. [Google Scholar] [CrossRef] [Green Version]
  58. Ko, Y.-L.; Wang, S.-M.; Hsu, L.-A.; Chang, C.-J.; Chu, P.-H.; Cheng, N.-J.; Chen, W.-J.; Chiang, C.-W.; Lee, Y.-S. The Gln–Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998, 141, 259–264. [Google Scholar] [CrossRef]
Figure 1. Variants (SNPs) filtration and prioritization pipeline. MI: Myocardial infarction; SNPs: single nucleotide polymorphism; APOE; Apolipoprotein E: PON1; Paroxonase 1.
Figure 1. Variants (SNPs) filtration and prioritization pipeline. MI: Myocardial infarction; SNPs: single nucleotide polymorphism; APOE; Apolipoprotein E: PON1; Paroxonase 1.
Genes 14 00687 g001
Figure 2. WES results of study subjects.
Figure 2. WES results of study subjects.
Genes 14 00687 g002
Table 1. Co-morbidities in study subjects.
Table 1. Co-morbidities in study subjects.
DiseaseFrequency (f)p Value
CasesControl
HTN55%36%0.001
DM47.5%32%0.007
HCV0.00%0.00%0.000
HBV0.00%0.00%0.000
Abbreviations: HTN: Hypertension; DM: Diabetes mellitus; HCV: Hepatitis C virus; HBV: Hepatitis B virus.
Table 2. Sociodemographic characteristics of Study subjects.
Table 2. Sociodemographic characteristics of Study subjects.
VariablesCases n (f)Control n (f)p-Value
Gender 0.382
Male140 (70%)63 (63%)
Female60 (30%)37(37%)
Age (yrs)58.43 ±12.6556.63 ± 11.87˂0.001
Age (male)58.53 ± 11.5456.32 ± 10.76
Age (Female)56.23 ± 12.3154.12 ± 11.31
Lipid profile (mg/dL)
TC265 ± 15230 ± 12˂0.001
HDL-C58 ± 760 ± 5˂0.001
LDL-C125 ± 14100 ± 8˂0.001
TG158 ± 10135 ± 90.070
Address
Peshawar44 (22%)28 (28%)
Charsadda25(12.5%)14 (14%)
Mardan23 (11.5%)9 (9%)
Kohat27 (13.5%)10 (10%)
Swabi12 (6%)5 (5%)0.338
Nowshehra18 (9%)5 (5%)
Bannu6 (3%)9 (9%)
Risalpur6 (3%)1 (1%)
Dir7(3.5%)2 (2%)
Swat32 (16%)17 (17%)
Occupation
Business10 (5%)4 (4%)
Gov servant21 (10.5%)6 (6%)
Retired25 (12.5%)17 (17%)
Farming30 (15%)11 (11%)˂0.001
Housewife54 (27%)59 (59%)
Labor60 (30%)3 (3%)
Family History of MI
Yes111 (55.5%)21 (21%)˂0.001
No89 (44.5%)79 (79%)
Exercise
Yes60 (30%)70 (70%)0.029
No (sedentary)140 (70%)30 (30%)
Smoking
Yes117 (58.5%)26 (26%)0.096
No83 (41.5%)74 (74%)
Male smokers58.5%26 (26%)˂0.001
Female smokers0.00%0.00%
Diet & Drug Compliance
Yes106 (51.5%)86 (86%)˂0.001
No94 (48.5%)14 (14%)
Medication history (%)
Statin80%20%˂0.001
ACEIs25%22%0.542
ARBs20%18%0.482
Abbreviations: n (f): number (frequency); yrs: years; TC: total cholesterol; HDL-C: MI: Myocardial Infarction; high-density lipoprotein cholesterol: LDL-C; low-density lipoprotein cholesterol: TG; triglycerides: ACEIs; Angiotensin Converting Enzyme Inhibitors: ARBs; Angiotensin Receptor Blockers.
Table 3. APOE variants (n = 12) identified by WES in Pashtun ethnic population.
Table 3. APOE variants (n = 12) identified by WES in Pashtun ethnic population.
SNP IDGeneVariantChr PositionSIFT PredictionPolyPhen PredictionMinor Allele FrequencyRead Depth
CasesControlCasesControl
rs769445APOEC/T19:44905055TolBenign0.010.03230150
rs449647APOEA/T19:44905307TolBenign0.110.10130110
rs877973APOEC/A19:44906026TolBenign0.080.07280220
rs184686013APOEA/G19:44906286TolBenign0.040.05170150
rs429358APOET/C19:44908684DelProbably damaging0.190.08288150
rs769455APOEC/T19:44908783TolBenign0.030.04157120
rs7412APOEC/T19:44908822DelBenign0.080.01274140
rs199768005APOET/A19:44909057TolBenign0.020.03148130
rs374329439APOEC/T19:44909275TolBenign0.050.06170140
rs117656888APOEC/G19:44909484TolBenign0.070.08150170
rs1081105APOEA/C19:44909698TolBenign0.080.09120150
rs1081106APOET/C19:44910109TolBenign0.060.07180220
Abbreviations: SNP; single nucleotide polymorphism: APOE; Apolipoprotein E: Chr; chromosome.
Table 4. PON1 gene variants (SNPs) were reported by WES in the study population.
Table 4. PON1 gene variants (SNPs) were reported by WES in the study population.
SNP IDGeneVariantChr PositionSIFT PredictionPolyPhen PredictionMinor Allele Frequency (%)Read Depth
CasesControlCasesControl
rs372449149PON1G/A7:94928371TolBenign0.230.25234250
rs185623242PON1G/A7:94931521TolBenign0.300.28140330
rs369422555PON1C/G7:94931583TolBenign0.340.32546237
rs371803280PON1C/T7:94931624TolBenign0.450.43120235
rs370355032PON1G/A7:949337419TolBenign0.270.29543454
rs80019660PON1G/A7:94937419TolBenign0.120.16453123
rs662PON1T/C7:94937446Pathdamaging0.400.30543436
rs61736513PON1C/T7:94944679TolBenign0.440.47124453
rs371338407PON1G/C7:94944768TolBenign0.330.36123342
rs8545560PON1A/T7:94946084TolBenign0.080.01154234
rs149100710PON1C/T7:94947635TolBenign0.470.50452734
rs144612002PON1T/C7:94947638TolBenign0.380.35563542
rs138512790PON1A/G7:9494756TolBenign0.430.45745121
rs141665531PON1G/A7:94947661TolBenign0.310.34234534
rs146211440PON1A/C7:94953721TolBenign0.450.43523123
rs150657027PON1G/A7:94953771TolBenign0.230.25534213
Abbreviations: SNP; single nucleotide polymorphism: PON1; Paroxonase 1: Chr; chromosome.
Table 5. Genotypes and alleles distribution of APOE gene in MI patients and controls.
Table 5. Genotypes and alleles distribution of APOE gene in MI patients and controls.
GenotypesMI Patients (n = 200)Controls (n = 100)OR (95% CI)p Value
ɛ2/ɛ26 (3%)4 (4%)0.84 (0.26–2.94)0.841
ɛ2/ɛ320 (10%)15 (15%)0.65 (0.32–1.27)0.207
ɛ2/ɛ48 (4%)6 (6%)0.72 (0.13–2.86)0.665
ɛ3/ɛ3127 (63.5)67(67%)1.20 (0.76–2.22)0.403
ɛ3/ɛ427 (13.5%)3 (3%)2.13 (1.32–2.65)0.031
ɛ4/ɛ412 (6%)5 (5%)0.45 (0.05–4.48)0.532
Alleles, n
ɛ240290.87 (0.34–2.06)0.462
ɛ31741521.70 (1.09–2.23)0.004
ɛ447192.11 (1.25–2.43)0.030
Allelic carriage rate
ɛ2 (+)34 (17%)25%ref-
ɛ2 (−)166 83%)75%0.614 (0.343–1.102)0.070
ɛ4 (+)47 (23.5)14%ref-
ɛ4 (−)153 (76.5)86%1.741 (0.919–3.297)0.057
Note: Odd ratio (95% CI) obtained from binary logistic regression analysis, p ≤ 0.05, was considered significant. MI: Myocardial infarction; OR: Odd ratio; CI: Confidence interval.
Table 6. Genotyping distribution and allele frequencies of PON1 gene (Q192R and L55M) polymorphisms in MI cases and controls.
Table 6. Genotyping distribution and allele frequencies of PON1 gene (Q192R and L55M) polymorphisms in MI cases and controls.
PON1 Gene GenotypesMI Cases n (f)Controls (f)Association Tests with MI
p ValueOR95% CI
Rs662-----
Total200 (100)100---
QQ (GG)72 (36%)49%ref--
QR (AG)96 (48%)42%0.1661.1600.844–1.523
RR (AA)32(16%)9%0.0481.5231.087–2.132
Allele frequency (n)
Q (G)240 (60)70%ref--
R (A)160 (40)30%0.0481.3530.959–1.910
Allelic carriage rate
Q (+)168 (84)51%ref
Q (−)32 (16)49%05.0442.926–8.696
R (+)128 (64)74%ref
R (−)72 (36)26%0.0060.6251.24–2.763
L55M variant polymorphism
Total
LL54.08 (27.04%)24.01%ref--
LM99.84(49.92%)49.98%0.5001.0150.798–1.291
MM46.08 (23.04%)26.01%0.3570.8980.592–1.363
Allele frequency (n)
L20898ref--
M192.031020.4020.9550.751–1.216
Allelic carriage rate
L (+)153.9273.99ref
L (−)46.0826.010.0581.5560.931–2.598
M (+)145.9275.99ref
M (−)54.0824.010.5790.8330.478–1.449
Abbreviations: MI: Myocardial infarction; PON1: Paroxonase1; Q: glutamine; R: arginine; L: leucine; M, methionine, OD: Odd ratio; CI: confidence interval (A p ≤ 0.05 was statistically considered significant).
Table 7. Logistic regression analysis of the risk of MI in the Pashtun population.
Table 7. Logistic regression analysis of the risk of MI in the Pashtun population.
VariableCrude ValuesAdjusted Values
β-Coefficientp ValueOR (95% CI)β-Coefficientp ValueOR (95% CI)
Age0.051˂0.0011.04 (1.21–1.78)0.042˂0.0011.03 (1.04–1.85)
Gender0.6120.3820.85 (0.43–0.75)0.5420.2570.272 (0.41–0.68)
Smoking1.243˂0.0011.75 (1.32–1.76)1.121˂0.0011.56 (1.27–1.58)
Family history of MI0.032˂0.0011.25 (1.12–2.07)0.21˂0.0011.04 (1.11–1.98)
HTN1.132˂0.0012.12 (1.42–1.93)1.032˂0.0012.01 (1.25–1.87)
DM1.5450.0071.43 (1.65–2.01)1.4230.0051.36 (1.54–1.98)
TC0.063˂0.0011.73 (1.65–2.32)0.051˂0.0011.71 (1.67–2.32)
LDL-C0.045˂0.0011.54 (1.32–2.15)0.032˂0.0011.45 (1.25–2.01)
ɛ4 allele0.4220.0302.11 (1.25–2.43)0.3210.0241.98 (1.16–2.36)
R allele0.3620.0481.35 (0.95–1.91)0.2340.0371.25 (1.22–2.43)
Note: OR: Odd ratio; CI: Confidence interval; MI: Myocardial infarction: HTN: Hypertension; DM: Diabetes mellitus; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol. Adjusted indicates results adjusted for covaries, i.e., age, gender, smoking, family history of MI, DM, HTN, and lipid parameters.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rahman, N.; Zakiullah; Jan, A.; Saeed, M.; Khan, M.A.; Parveen, Z.; Iqbal, J.; Ali, S.; Shah, W.A.; Akbar, R.; et al. Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan. Genes 2023, 14, 687. https://doi.org/10.3390/genes14030687

AMA Style

Rahman N, Zakiullah, Jan A, Saeed M, Khan MA, Parveen Z, Iqbal J, Ali S, Shah WA, Akbar R, et al. Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan. Genes. 2023; 14(3):687. https://doi.org/10.3390/genes14030687

Chicago/Turabian Style

Rahman, Naveed, Zakiullah, Asif Jan, Muhammad Saeed, Muhammad Asghar Khan, Zahida Parveen, Javaid Iqbal, Sajid Ali, Waheed Ali Shah, Rani Akbar, and et al. 2023. "Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan" Genes 14, no. 3: 687. https://doi.org/10.3390/genes14030687

APA Style

Rahman, N., Zakiullah, Jan, A., Saeed, M., Khan, M. A., Parveen, Z., Iqbal, J., Ali, S., Shah, W. A., Akbar, R., & Khuda, F. (2023). Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan. Genes, 14(3), 687. https://doi.org/10.3390/genes14030687

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop